Metastatic prostate cancer is a type of cancer that began in the prostate gland and has spread to other areas of the body, ...

Bladder cancer staging is crucial for operation planning and cancer assessment. Deep Convolutional Neural Networks (DCNNs) have been widely used to classify the bladder tumor images to identify cancer ...

Bladder cancer is a difficult disease to manage and requires long-term follow-up after treatment including the use of cystoscopy for detecting recurrence. In this Review the role of ...

Treatment recommendations for all stages of bladder cancer have been proposed in the form of clinical guidelines from the European Association of Urology and the American Urological Association ...

A Surprising Marker: The Ovarian Cancer Clue In a twist no one expected, researchers found that many HV tumors express CA125, a marker known for its role in ovarian cancer. This means that 1 in 4 ...

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30 th and June 3 rd, 2025, was host to a kidney and bladder cancers poster session.

Yang, H., et al. (2025). Bladder cancer variants share aggressive features including a CA125+ cell state and targetable TM4SF1 expression. Nature Communications. doi.org/10.1038/s41467-025-59888-8.

Lymph Node-positive Bladder Cancer Surgical, Pathologic, Molecular and Prognostic Aspects Jose A Pedrosa; Michael O Koch; Liang Cheng Disclosures Expert Rev Anticancer Ther. 2013;13 (11):1281-1295.

Bladder cancer (BCa) is the most costly solid tumor owing to its high recurrence. Relapsed cancer is known to acquire chemoresistant features after standard intravesical chemotherapy. This cancer ...

The American medicines regulator has approved Zusduri (mitomycin), a hydrogel-based treatment developed by US biotech UroGen Pharma (Nasdaq: URGN), for adults with recurrent low-grade, ...

Despite failing to secure the backing of an external panel of advisors, UroGen won the FDA’s approval on Thursday for its intravesical drug mitomycin for the treatment of low-grade intermediate-risk ...

LG-IR-NMIBC affects around 82,000 people in the U.S. every year and of those, an estimated 59,000 are recurrent. Bladder cancer primarily affects older populations with increased risk of comorbidities ...